You are here

Clinical Trials: Cord Blood

Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
Condition:   Primary Graft Failure
Intervention:   Drug: FLT imaging and TK1 blood measurements
Sponsors:   University of Oklahoma;   Children's National Health System;   University of Michigan
Not yet recruiting
Conditions:   Bone Marrow Failure Syndrome;   Thalassemia;   Sickle Cell Disease;   Diamond Blackfan Anemia;   Acquired Neutropenia in Newborn;   Acquired Anemia Hemolytic;   Acquired Thrombocytopenia;   Hemophagocytic Lymphohistiocytoses;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Common Variable Immunodeficiency;   X-linked Lymphoproliferative Disease;   Severe Combined Immunodeficiency;   Hurler Syndrome;   Mannosidosis;   Adrenoleukodystrophy
Interventions:   Drug: Thiotepa--single daily dose;   Drug: Thiotepa--escalated dose
Sponsor:   University of Florida
Not yet recruiting
Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Myelodysplastic Syndromes;   Other Acute Leukemias
Interventions:   Biological: Unmanipulated Umbilical Cord Blood (UCB);   Biological: AB-110
Sponsor:   Angiocrine Bioscience
Not yet recruiting
Condition:   Cerebral Palsy
Interventions:   Biological: Infusion of allogeneic umbilical cord blood;   Biological: Infusion of MSCs
Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation
Not yet recruiting
Condition:   Multiple Myeloma
Intervention:   Biological: ECT-001 (UM171) expanded cord blood
Sponsors:   Ciusss de L'Est de l'Île de Montréal;   ExcellThera;   Centre de Commercialisation en Immunothérapie du Cancer (C3i)
Not yet recruiting
Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting
Conditions:   Hypoplastic Left Heart Syndrome;   Heart Defects, Congenital;   Pediatric Disorder
Intervention:   Biological: Autologous Human Placental Cord Blood Mononuclear Cells
Sponsor:   Murdoch Childrens Research Institute
Not yet recruiting
Conditions:   Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation;   Recurrent Lip and Oral Cavity Carcinoma;   Recurrent Malignant Endocrine Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Male Reproductive System Neoplasm;   Recurrent Malignant Mesothelioma;   Recurrent Malignant Neoplasm of Multiple Primary Sites;   Recurrent Malignant Oral Neoplasm;   Recurrent Malignant Pharyngeal Neoplasm;   Recurrent Malignant Skin Neoplasm;   Recurrent Malignant Soft Tissue Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Malignant Thyroid Gland Neoplasm;   Recurrent Malignant Urinary System Neoplasm;   Recurrent Melanoma of the Skin;   Refractory Cutaneous Melanoma;   Refractory Malignant Bone Neoplasm;   Refractory Malignant Endocrine Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm;   Refractory Malignant Male Reproductive System Neoplasm;   Refractory Malignant Mesothelioma;   Refractory Malignant Neoplasm of Multiple Primary Sites;   Refractory Malignant Oral Neoplasm;   Refractory Malignant Pharyngeal Neoplasm;   Refractory Malignant Skin Neoplasm;   Refractory Malignant Soft Tissue Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Malignant Thyroid Gland Neoplasm;   Refractory Malignant Urinary System Neoplasm
Interventions:   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cyclophosphamide;   Drug: Etoposide
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting
Condition:   Inherited Metabolic Disorders (IMD)
Intervention:   Drug: MGTA-456
Sponsor:   Magenta Therapeutics, Inc.
Not yet recruiting

Pages